Literature DB >> 21537654

Quality of life assessment in patients with cystic fibrosis by means of the Cystic Fibrosis Questionnaire.

Milena Antonelli Cohen1, Maria Ângela Gonçalves de Oliveira Ribeiro, Antonio Fernando Ribeiro, José Dirceu Ribeiro, André Moreno Morcillo.   

Abstract

OBJECTIVE: To assess the quality of life (QoL) of patients with cystic fibrosis (CF) followed at a university referral center for CF.
METHODS: A cross-sectional study involving application of the Cystic Fibrosis Questionnaire (CFQ) and Shwachman score in CF patients between April of 2008 and June of 2009.
RESULTS: The sample consisted of 75 patients. The mean age was 12.5 ± 5.1 years (range, 6.1-26.4 years). The patients were divided into three groups by age in years: group I (< 12), II (12-14), and III (> 14). The highest and lowest CFQ scores were for the nutrition domain in group III (89.3 ± 16.2) and the social domain in group II (59.5 ± 22.3), respectively. Groups I and III differed significantly regarding the treatment domain (p = 0.001). Regarding Shwachman scores, there were significant differences between patients scoring < 70 and those scoring > 70 in the social (group I; p = 0.045), respiratory (group II; p = 0.053), and digestive (p = 0.042) domains. In group III, severity did not correlate with QoL. In groups I and II, patients with an FEV1 < 80% of predicted did not differ from other patients for any CFQ domain. However, in group III, values for the following domains were significantly lower in patients with an FEV1 < 80%: physical (p = 0.012); body image (p = 0.031); respiratory (p = 0.023), emotional (p = 0.041); and social role (p = 0.024).
CONCLUSIONS: It is important to assess QoL in CF patients, because it can improve treatment compliance.

Entities:  

Mesh:

Year:  2011        PMID: 21537654     DOI: 10.1590/s1806-37132011000200008

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  5 in total

1.  Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice.

Authors:  Caroline Rung Elsas; Elinor Langfelder Schwind; Laura Hercher; Michael J Smith; Kara Gardner Young
Journal:  J Genet Couns       Date:  2016-06-09       Impact factor: 2.537

2.  Respiratory therapy: a problem among children and adolescents with cystic fibrosis.

Authors:  Taiane Dos Santos Feiten; Josani Silva Flores; Bruna Luciano Farias; Paula Maria Eidt Rovedder; Eunice Gus Camargo; Paulo de Tarso Roth Dalcin; Bruna Ziegler
Journal:  J Bras Pneumol       Date:  2016 Jan-Feb       Impact factor: 2.624

3.  Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis.

Authors:  A K M Ashiqul Haque; Alexander Dewerth; Justin S Antony; Joachim Riethmüller; Georg R Schweizer; Petra Weinmann; Ngadhnjim Latifi; Hanzey Yasar; Nicoletta Pedemonte; Elvira Sondo; Brian Weidensee; Anjali Ralhan; Julie Laval; Patrick Schlegel; Christian Seitz; Brigitta Loretz; Claus-Michael Lehr; Rupert Handgretinger; Michael S D Kormann
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

4.  Quality of life amongst adolescents and young adults with cystic fibrosis: correlations with clinical outcomes.

Authors:  Daniela W Gancz; Maristela T Cunha; Claudio Leone; Joaquim C Rodrigues; Fabíola V Adde
Journal:  Clinics (Sao Paulo)       Date:  2018-10-18       Impact factor: 2.365

5.  A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis.

Authors:  Irushi Ratnayake; Susannah Ahern; Rasa Ruseckaite
Journal:  BMJ Open       Date:  2020-10-01       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.